“The RAS Dam Has Broken”

ASP3082, a proteolysis targeting chimera that targets mutant KRASG12D, and elironrasib, a tri-complex inhibitor of KRASG12C in the "on" state, showed encouraging efficacy and safety in separate phase I trials.